Northern Ireland pharmaceutical group Galen has been granted a licence by the British Department of Health to begin marketing its first intravaginal ring-based product for hormone replacement therapy. This licence will allow Galen to begin selling the product which will be marketed to GPs through Galen's own 115-strong salesforce.